Tiba Biotech Partners with BARDA to Develop Groundbreaking Influenza Therapeutics

The $749,999 contract, awarded through a highly competitive review process, will support the early-stage development of Tiba Biotech’s therapeutic platform as part of BARDA’s Flexible and Strategic Therapeutics (FASTx) program. This program is designed to advance cutting-edge therapeutic technologies, such as RNA-mediated interference (RNAi), which can be rapidly deployed in response to emerging viral threats.

Tiba Biotech’s initial focus under this partnership will be the development of a prototype RNAi-based therapeutic targeting the highly conserved viral nucleoprotein of H1N1 influenza. The therapeutic will be delivered via Tiba’s proprietary RNABL platform.

Dr. Jasdave Chahal, co-founder and lead investigator of the project, expressed his excitement about the award: “We are excited to receive this BARDA award, which will advance Tiba’s innovative approach to combating influenza and other viral threats. We believe our technology has the potential to transform the landscape of RNA therapeutics.”

This initiative builds on Tiba’s ongoing work to combat influenza pandemic threats. Notably, Tiba is developing a novel multi-antigen mRNA-based H7N9 flu vaccine, funded under a Phase II Small Business Innovation Research (SBIR) award from the National Institutes of Health (NIH). Tiba is also engaged in ongoing collaborations with the Collaborative Influenza Vaccine Innovation Centers (CIVICs).

Furthermore, Tiba Biotech was recently accepted into BLUE KNIGHT, a joint initiative between Johnson & Johnson Innovation – JLABS and BARDA, which seeks to drive innovation in addressing future health threats.

This project is fully supported by federal funds from the Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50124C00014.

This partnership marks a significant step forward in the fight against influenza, leveraging Tiba Biotech’s cutting-edge RNAi technology to develop rapid-response therapeutics that could play a crucial role in addressing current and future viral threats.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services